Integrating SPRAVATO® (esketamine) nasal spray into your practice offers a powerful, FDA-approved option for adults with treatment-resistant depression (TRD) and for those with major depressive disorder (MDD) experiencing acute suicidal ideation or behavior. For clinicians, this represents a significant opportunity to provide rapid relief to patients who have not found success with at least two other antidepressant treatments. The journey to becoming a SPRAVATO® provider involves careful planning, adherence to safety protocols, and a commitment to a structured patient experience. Think of it as adding a specialized wing to your clinical offerings—one that requires a unique blueprint for patient care, safety, and administration. By understanding the core requirements, you can create a new avenue of hope for your most challenging cases.
Before a single dose is administered, identifying the right patient is paramount. According to FDA guidelines, SPRAVATO® is indicated for adults with TRD who have failed to respond adequately to at least two different oral antidepressants in the current depressive episode. It's also approved for patients with MDD who have acute suicidal thoughts or behaviors. These patients must continue taking an oral antidepressant alongside their SPRAVATO® treatment. The screening process is analogous to qualifying a patient for a specialized surgical procedure; it requires a thorough review of their treatment history, current symptoms, and comorbidities. A comprehensive psychiatric evaluation is necessary to confirm the diagnosis and rule out contraindications, such as a history of psychosis or substance use disorders that could be exacerbated by the dissociative effects of esketamine. Explore how a meticulous patient selection process can lead to better outcomes and safer administration within your practice.
The cornerstone of safe SPRAVATO® administration is the Risk Evaluation and Mitigation Strategy (REMS) program, mandated by the FDA. This isn't just paperwork; it's a crucial safety framework designed to minimize risks associated with sedation, dissociation, and potential for misuse. To become a certified treatment center, your practice must enroll in the REMS program, designating a lead prescriber who will oversee compliance. Every patient must also be enrolled in the patient registry before they can receive their first dose. After each treatment session, your clinic is required to submit a Patient Monitoring Form to the REMS database, confirming that all safety protocols were followed. Consider implementing a digital workflow using an EHR system, which can automate these submissions and reduce the administrative burden. Tools like Osmind EHR are designed to integrate with the REMS program, simplifying compliance and allowing you to focus more on patient care and less on clerical tasks.
The SPRAVATO® treatment protocol is structured in two distinct phases: induction and maintenance. The induction phase typically involves twice-weekly treatments for the first four weeks. If the patient responds well, they move into the maintenance phase, with sessions reduced to once a week for the next four weeks, and then to every one or two weeks thereafter, based on clinical judgment.
Here is a simplified timeline of a patient's journey through the initial phase of treatment:
Phase
Frequency
Duration
Induction
Twice a week
Weeks 1-4
Maintenance
Once a week
Weeks 5-8
Maintenance
Every 1-2 weeks
Week 9 and beyond
Each session is a self-contained medical procedure. The patient self-administers the nasal spray under your supervision and must then be monitored for at least two hours. During this time, you will monitor for sedation, dissociation, and changes in vital signs, particularly blood pressure. The patient cannot drive, operate heavy machinery, or make important decisions for the rest of the day. This two-hour observation period is non-negotiable and is a core component of the REMS program.
Creating the right physical space is essential for a positive patient experience and efficient workflow. Since patients will be in your office for over two hours per session, the environment should promote calm and relaxation. Many practices opt for private rooms equipped with comfortable recliners, blankets, eye masks, and headphones for patients to listen to calming music. If space is a constraint, a shared room with privacy screens can work well, allowing for simultaneous monitoring of multiple patients.
From a compliance standpoint, your facility must have a secure, locked safe for storing the SPRAVATO® medication, as it is a Schedule III controlled substance. You will also need basic medical monitoring equipment, such as a blood pressure cuff and pulse oximeter. Think of the treatment room as a sanctuary where the patient can comfortably navigate the therapeutic experience while your team ensures their safety.
Navigating the financial aspects of SPRAVATO® is a common concern for practices. There are two primary models for medication procurement and billing: "buy and bill" or using a specialty pharmacy. In the "buy and bill" model, your practice purchases the medication directly and bills the patient's medical insurance for both the drug and its administration. Alternatively, the patient's prescription can be sent to a REMS-certified specialty pharmacy, which then ships the patient-specific dose to your clinic. In this case, you would only bill for the administration and monitoring services.
Successful reimbursement hinges on using the correct codes. For the "buy and bill" method with Medicare and some commercial payers, you'll use HCPCS codes like G2082 (for a 56 mg dose) and G2083 (for an 84 mg dose), which bundle the cost of the drug and its administration. For other commercial payers, you may need to use S0013 to bill for the drug itself. The administration and monitoring portion of the visit is typically billed using Evaluation and Management (E/M) codes, such as 99212-99215, along with prolonged service codes like 99415, 99416, or 99417 to account for the two-hour observation period. For patients facing coverage gaps, the Janssen CarePath program can offer financial assistance. Learn more about how to optimize your billing practices to ensure financial viability.
While SPRAVATO® is a powerful pharmacological intervention, its benefits can be significantly enhanced when paired with psychotherapy. The neuroplasticity-promoting effects of esketamine can create a unique window of opportunity for therapeutic processing. Some clinicians are adopting a model that includes "preparation" and "integration" sessions. A preparation session occurs before the first SPRAVATO® treatment, allowing the therapist to set expectations, establish a therapeutic alliance, and develop coping strategies for the dissociative experience.
Following a SPRAVATO® session, an "integration" session helps the patient process insights, emotions, and memories that may have surfaced during the treatment. This is analogous to how a physical therapist helps a patient regain function after surgery; the integration session helps translate the biochemical changes in the brain into lasting psychological growth. By weaving psychotherapy into the treatment protocol, you can help patients build a more holistic and effective treatment journey. Consider implementing this model to provide a more holistic and effective treatment journey.
The administrative demands of a SPRAVATO® session, from REMS compliance to detailed billing, are significant. Each step of the two-hour monitoring period—vital sign checks, patient-reported side effects, clinical observations—must be meticulously documented. This is where an AI-powered medical scribe like S10.ai can transform your workflow. Instead of being tethered to a keyboard, you can focus entirely on the patient. S10.ai listens to the ambient conversation and clinical interactions during the session, automatically generating a precise, clinically accurate note. It captures the nuances of the patient's experience and your medical assessments in real-time, ensuring that your documentation is both comprehensive and compliant. Explore how integrating an AI scribe can dramatically reduce your administrative burden, mitigate documentation errors, and free you to provide the attentive, high-quality care your SPRAVATO® patients deserve.
What are the essential first steps for a private practice to become a certified SPRAVATO® treatment center?
To begin offering SPRAVATO®, your practice must first enroll in the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program. This is a critical safety requirement. You'll need to designate a lead prescriber, ensure all treating clinicians are certified, and have a process to enroll every patient into the patient registry before their first dose. Think of it as getting the necessary permits before building a new facility; it ensures a foundation of safety and compliance. Additionally, you must establish protocols for the mandatory two-hour post-treatment monitoring period, including having the right space and equipment to observe patients for sedation, dissociation, and blood pressure changes. Consider implementing an EHR system like Osmind, which can help automate REMS submissions and streamline this entire process.
How can my practice effectively manage the complex billing and reimbursement process for SPRAVATO®?
Navigating SPRAVATO® reimbursement requires a clear strategy, as it's a common pain point discussed in clinician forums. Practices typically choose between a "buy and bill" model, where you purchase the drug and bill for it alongside administration, or a specialty pharmacy model, where the pharmacy handles the medication billing. For the administration and the required two-hour monitoring, you'll use a combination of Evaluation and Management (E/M) codes (e.g., 99212-99215) and prolonged service codes (e.g., 99417) to accurately capture the time and intensity of the service. It is crucial to get prior authorization and verify coverage for each patient, as requirements vary significantly between payers. Explore how partnering with a service that specializes in benefits verification and billing can significantly reduce claim denials and administrative overhead.
Beyond the medication itself, what does a comprehensive SPRAVATO® treatment plan that maximizes patient outcomes look like?
For the best long-term results, SPRAVATO® should not be a standalone treatment. Leading practices integrate it within a holistic care plan that includes ongoing oral antidepressant use and psychotherapy. The period following a SPRAVATO® session can create a unique neuroplastic state, making it an ideal time for therapeutic work. Consider structuring your program to include "integration" therapy sessions where patients can process their experiences and insights from the treatment. Furthermore, encouraging lifestyle modifications such as regular exercise, mindfulness practices, and a consistent sleep schedule can help sustain the benefits. Learn more about how combining these modalities creates a synergistic effect, helping patients build resilience and translate the rapid symptom relief from SPRAVATO® into lasting recovery.
Hey, we're s10.ai. We're determined to make healthcare professionals more efficient. Take our Practice Efficiency Assessment to see how much time your practice could save. Our only question is, will it be your practice?
We help practices save hours every week with smart automation and medical reference tools.
+200 Specialists
Employees4 Countries
Operating across the US, UK, Canada and AustraliaWe work with leading healthcare organizations and global enterprises.